For the Inventor, By the Inventor

Enter inventor name

Lafayette, CA, United States of America

James J Devlin

USPTO Granted Patents = 39 (Patent Applications = 29)

CIPO Patents = 21 (Patent Applications = 1)

EPO Patents = 32 (Patent Applications = 20)

Average Co-Inventor Count = 4.1

ph-index = 8

Forward Citations = 170(Granted Patents)

Location History:

Foster City, CA (US) (2007)
Lafayette, CA (US) (1992 - 2024)

Company Filing History:

Celera Corporation

Berlex Laboratories, Inc.

Pharmacopeia Drug Discovery, Inc.

4. 3 out of 479

Quest Diagnostics Investments, Inc.

5. 1 out of 212

Cetus Corporation

6. 1 out of 496

Applera Corporation

Lieden University Medical Center (lumc)

Celera Coporation

Berlax Laboratories, Inc.

10. 1 out of 101

Pharmacopeia Inc.

11. 3 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1992-2025

Loading Chart...

Loading Chart...

Loading Chart...

39 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12332236 - Methods for quantitation of insulin and C-peptide (2025-06-17),

2. 12077825 - Genetic polymorphisms associated with stroke, methods of detection and uses thereof (2024-09-03),

3. 12025610 - Methods for quantitation of insulin and C-peptide (2024-07-02),

4. 11814684 - Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof (2023-11-14),

5. 11708610 - Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof (2023-07-25),

6. 11408034 - Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof (2022-08-09),

7. 11401555 - Genetic polymorphisms associated with stroke, methods of detection and uses thereof (2022-08-02),

8. 11124834 - Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof (2021-09-21),

9. 11041209 - Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof (2021-06-22),

10. 10988809 - Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof (2021-04-27),

11. 10983108 - Methods for quantitation of insulin and C-peptide (2021-04-20),

12. 10982281 - Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof (2021-04-20),

13. 10584384 - Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof (2020-03-10),

14. 10550434 - Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof (2020-02-04),

15. 10435749 - Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof (2019-10-08),

Title: The Innovative Work of Inventor James J Devlin

Introduction:

James J Devlin, a prolific inventor based in Lafayette, CA (US), has made significant contributions to the field of genetics and cardiovascular health with an impressive 36 patents to his name.

Latest Patents:

Devlin's latest patents include groundbreaking discoveries in the field of genetic polymorphisms associated with coronary events and drug response, showcasing his commitment to advancing medical research. These patents focus on identifying nucleic acid molecules containing specific polymorphisms linked to cardiovascular disorders and individual responses to statin treatment.

Career Highlights:

Having worked at reputable companies such as Celera Corporation and Berlex Laboratories, Inc., Devlin has honed his expertise in genetic research and pharmaceutical development. His innovative approach to scientific inquiry has led to numerous patents that have the potential to revolutionize the treatment of cardiovascular diseases.

Collaborations:

Throughout his career, Devlin has collaborated with esteemed professionals in the field, including coworkers like Olga Iakoubova and Damian O Arnaiz. These collaborations have undoubtedly enriched his research endeavors and contributed to the successful outcomes of his inventions.

Conclusion:

Inventor James J Devlin's remarkable body of work serves as a testament to his dedication to advancing medical science and improving patient outcomes in the realm of cardiovascular health. His innovative patents stand as a testament to his commitment to pushing the boundaries of genetic research and personalized medicine.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…